Basis of Presentation and Significant Accounting Policies - Impact on Statement of Operations (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions |
3 Months Ended | 6 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2018 |
Jul. 01, 2017 |
Jun. 30, 2018 |
Jul. 01, 2017 |
||||||||||||
| Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |||||||||||||||
| Net revenue | $ 1,151 | $ 2,329 | |||||||||||||
| Cost of sales | [1] | $ 1,104 | 765 | $ 2,154 | 1,565 | ||||||||||
| Gross margin | [1] | 652 | 386 | 1,249 | 764 | ||||||||||
| Research and development | [1] | 357 | 285 | 700 | 556 | ||||||||||
| Marketing, general and administrative | [1] | 142 | 127 | 276 | 250 | ||||||||||
| Licensing gain | [1] | 0 | (25) | 0 | (52) | ||||||||||
| Operating income | [1] | 153 | (1) | 273 | 10 | ||||||||||
| Interest expense | [1] | (31) | (32) | (62) | (64) | ||||||||||
| Other income (expense), net | [1] | 1 | (3) | 2 | (8) | ||||||||||
| Income (loss) before equity loss and income taxes | [1] | 123 | (36) | 213 | (62) | ||||||||||
| Provision for income taxes | [1] | 6 | 3 | 14 | 8 | ||||||||||
| Equity loss in investee | [1] | (1) | (3) | (2) | (5) | ||||||||||
| Net income (loss) | [1],[2] | $ 116 | $ (42) | $ 197 | [3],[4] | $ (75) | [3],[4] | ||||||||
| Earnings (loss) per share | |||||||||||||||
| Basic (in usd per share) | [1] | $ 0.12 | $ (0.04) | $ 0.20 | $ (0.08) | ||||||||||
| Diluted (in usd per share) | [1] | $ 0.11 | $ (0.04) | $ 0.19 | $ (0.08) | ||||||||||
| Shares used in per share calculation | |||||||||||||||
| Basic (in shares) | [1] | 972 | 945 | 970 | 942 | ||||||||||
| Diluted (in shares) | [1] | 1,147 | 945 | 1,043 | 942 | ||||||||||
| As Previously Reported | |||||||||||||||
| Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |||||||||||||||
| Net revenue | $ 1,222 | $ 2,206 | |||||||||||||
| Cost of sales | 818 | 1,471 | |||||||||||||
| Gross margin | 404 | 735 | |||||||||||||
| Research and development | 279 | 545 | |||||||||||||
| Marketing, general and administrative | 125 | 246 | |||||||||||||
| Licensing gain | (25) | (52) | |||||||||||||
| Operating income | 25 | (4) | |||||||||||||
| Interest expense | (32) | (64) | |||||||||||||
| Other income (expense), net | (3) | (8) | |||||||||||||
| Income (loss) before equity loss and income taxes | (10) | (76) | |||||||||||||
| Provision for income taxes | 3 | 8 | |||||||||||||
| Equity loss in investee | (3) | (5) | |||||||||||||
| Net income (loss) | $ (16) | $ (89) | |||||||||||||
| Earnings (loss) per share | |||||||||||||||
| Basic (in usd per share) | $ (0.02) | $ (0.09) | |||||||||||||
| Diluted (in usd per share) | $ (0.02) | $ (0.09) | |||||||||||||
| Shares used in per share calculation | |||||||||||||||
| Basic (in shares) | 945 | 942 | |||||||||||||
| Diluted (in shares) | 945 | 942 | |||||||||||||
| Accounting Standards Update 2014-09 | Adjustment | |||||||||||||||
| Revenue, Initial Application Period Cumulative Effect Transition [Line Items] | |||||||||||||||
| Net revenue | $ (71) | $ 123 | |||||||||||||
| Cost of sales | (53) | 94 | |||||||||||||
| Gross margin | (18) | 29 | |||||||||||||
| Research and development | 6 | 11 | |||||||||||||
| Marketing, general and administrative | 2 | 4 | |||||||||||||
| Licensing gain | 0 | 0 | |||||||||||||
| Operating income | (26) | 14 | |||||||||||||
| Interest expense | 0 | 0 | |||||||||||||
| Other income (expense), net | 0 | 0 | |||||||||||||
| Income (loss) before equity loss and income taxes | (26) | 14 | |||||||||||||
| Provision for income taxes | 0 | 0 | |||||||||||||
| Equity loss in investee | 0 | 0 | |||||||||||||
| Net income (loss) | $ (26) | $ 14 | |||||||||||||
| Earnings (loss) per share | |||||||||||||||
| Basic (in usd per share) | $ (0.02) | $ 0.01 | |||||||||||||
| Diluted (in usd per share) | $ (0.02) | $ 0.01 | |||||||||||||
| |||||||||||||||
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|